TAP Pharmaceutical gets FDA OK for Prevacid injection

JennySpitz

SAN FRANCISCO (CBS.MW) -- TAP Pharmaceutical, a joint venture between Abbott Laboratories
ABT, -1.04%
and Japan's Takeda Chemical, announced late Tuesday that the Food and Drug Administration has approved its intravenous formulation of Prevacid. Currently, Prevacid is marketed only in oral form for heartburn-related relief and to help heal damage to the esophagus. The company is advising that the injected form of the drug only be used on patients until they are able to swallow pills. Ahead of the news, shares of Abbott closed down 20 cents at $41.01.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.